Adams Catherine Owen - 24 Mar 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ACAD
Reported as of: 24 Mar 2026
Net transaction value: -$249,932
SEC form: 4
Accepted by SEC: 26 Mar 2026, 20:00:15 UTC
Prior SEC filing: 10 Mar 2026
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

Adams Catherine Owen filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 26 Mar 2026.

Key facts

This page summarizes Adams Catherine Owen's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Mar 2026, 20:00.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: -$249,932.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816838 Primary reporting owner

Owen Adams Catherine

Relationship: Chief Executive Officer, Director
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 26 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Options Exercise

Transaction value
Shares: +23,509
Change %: +801%
Price: $0.000000^*
Shares after: 26,444
Date: 24 Mar 2026
Ownership: Direct
Footnotes: F1, F2

ACAD transaction

Common Stock

Sale

Transaction value: $249,932
Shares: -11,641
Change %: -44%
Price: $21.47
Shares after: 14,803
Date: 25 Mar 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACAD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -23,509
Change %: -25%
Price: $0.000000^*
Shares after: 70,530
Date: 24 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,509
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes 2,935 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan.

Footnote F3

The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

Footnote F4

The restricted stock units vest in four equal annual installments beginning March 24, 2026.